Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the webspellchecker domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/gulfindex35/public_html/ptbreports.org/wp-includes/functions.php on line 6131
Drug Review: Eflapegrastim – PTB Reports
Article

Drug Review: Eflapegrastim

Written by admin

PTB Reports, 2023, 9, 2, 52-53.
DOI: 10.5530/PTB.2023.9.8
Published: November 2023
Type: Drug Review
Authors: Juman Alsaab

Author(s) affiliations:

Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Registrations: It had been registered in the following countries: United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (S.A.) Trade name (USA); ROLVEDON Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (29.1.2023). General Information: Registered Company: Spectrum Pharmaceuticals. Regulatory Status: R.X. Mechanism of Action: A recombinant human granulocyte growth factor activates signaling pathways that affect cell differentiation, proliferation, migration, and survival by binding to G-CSF receptors on myeloid progenitor cells and neutrophils.

View: DOWNLOAD PDF  | DOWNLOAD SLIDE